Compare Dr. Reddys with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs UNICHEM LAB - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB UNICHEM LAB DR. REDDYS LAB/
UNICHEM LAB
 
P/E (TTM) x 17.0 -95.9 - View Chart
P/BV x 3.3 0.5 618.6% View Chart
Dividend Yield % 0.7 2.6 27.6%  

Financials

 DR. REDDYS LAB   UNICHEM LAB
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
UNICHEM LAB
Mar-19
DR. REDDYS LAB/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs2,875292 984.6%   
Low Rs1,888182 1,037.4%   
Sales per share (Unadj.) Rs930.2167.7 554.8%  
Earnings per share (Unadj.) Rs117.4-3.6 -3,234.1%  
Cash flow per share (Unadj.) Rs185.85.9 3,126.3%  
Dividends per share (Unadj.) Rs20.004.00 500.0%  
Dividend yield (eoy) %0.81.7 49.8%  
Book value per share (Unadj.) Rs844.4372.3 226.8%  
Shares outstanding (eoy) m166.0770.38 236.0%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.61.4 181.1%   
Avg P/E ratio x20.3-65.3 -31.1%  
P/CF ratio (eoy) x12.839.9 32.1%  
Price / Book Value ratio x2.80.6 443.0%  
Dividend payout %17.0-110.2 -15.5%   
Avg Mkt Cap Rs m395,49616,680 2,371.1%   
No. of employees `00022.02.6 844.2%   
Total wages/salary Rs m33,5622,393 1,402.4%   
Avg. sales/employee Rs Th7,032.84,535.2 155.1%   
Avg. wages/employee Rs Th1,527.9919.8 166.1%   
Avg. net profit/employee Rs Th887.7-98.2 -904.0%   
INCOME DATA
Net Sales Rs m154,48211,801 1,309.1%  
Other income Rs m3,375984 343.0%   
Total revenues Rs m157,85712,785 1,234.7%   
Gross profit Rs m31,782-835 -3,806.7%  
Depreciation Rs m11,348674 1,684.4%   
Interest Rs m88975 1,182.2%   
Profit before tax Rs m22,920-600 -3,821.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m4381 62,571.4%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,858-343 -1,123.2%   
Profit after tax Rs m19,500-256 -7,631.2%  
Gross profit margin %20.6-7.1 -290.8%  
Effective tax rate %16.857.3 29.4%   
Net profit margin %12.6-2.2 -582.9%  
BALANCE SHEET DATA
Current assets Rs m111,10120,384 545.0%   
Current liabilities Rs m58,9735,029 1,172.6%   
Net working cap to sales %33.7130.1 25.9%  
Current ratio x1.94.1 46.5%  
Inventory Days Days79105 75.7%  
Debtors Days Days94135 69.8%  
Net fixed assets Rs m101,2459,023 1,122.0%   
Share capital Rs m830141 589.5%   
"Free" reserves Rs m139,40626,058 535.0%   
Net worth Rs m140,23626,199 535.3%   
Long term debt Rs m22,0000-   
Total assets Rs m224,65631,496 713.3%  
Interest coverage x26.8-7.0 -384.0%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.70.4 183.5%   
Return on assets %9.1-0.6 -1,585.1%  
Return on equity %13.9-1.0 -1,425.7%  
Return on capital %14.9-2.0 -747.5%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,6738,188 1,083.0%   
Fx outflow Rs m19,104596 3,205.4%   
Net fx Rs m69,5697,592 916.3%   
CASH FLOW
From Operations Rs m28,704-3,278 -875.7%  
From Investments Rs m-7,727-2,860 270.2%  
From Financial Activity Rs m-21,326-24 88,124.0%  
Net Cashflow Rs m-314-4,690 6.7%  

Share Holding

Indian Promoters % 25.5 50.1 50.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 15.1 35.8%  
FIIs % 35.3 3.0 1,176.7%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 31.7 48.3%  
Shareholders   75,885 20,176 376.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 229 Points Lower; Banking and Metal Stocks Witness Selling(Closing)

Indian share markets fell sharply during closing hours today amid weak global cues and disappointing domestic factory output data.

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 13, 2019 03:37 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS